dc.contributor.author |
Farkas, Henriette |
|
dc.contributor.author |
Martinez-Saguer I |
|
dc.contributor.author |
Bork K |
|
dc.contributor.author |
Bowen T |
|
dc.contributor.author |
Craig T |
|
dc.contributor.author |
Frank M |
|
dc.contributor.author |
Germenis AE |
|
dc.contributor.author |
Grumach AS |
|
dc.contributor.author |
Luczay, Andrea |
|
dc.contributor.author |
Varga, Lilian |
|
dc.contributor.author |
Zanichelli A |
|
dc.contributor.author |
HAWK |
|
dc.date.accessioned |
2017-04-10T13:18:28Z |
|
dc.date.available |
2017-04-10T13:18:28Z |
|
dc.date.issued |
2017 |
|
dc.identifier |
84987949061 |
|
dc.identifier.citation |
pagination=300-313;
journalVolume=72;
journalIssueNumber=2;
journalTitle=ALLERGY; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/4072 |
|
dc.identifier.uri |
doi:10.1111/all.13001 |
|
dc.description.abstract |
BACKGROUND: The consensus documents published to date on hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) have focused on adult patients. Many of the previous recommendations have not been adapted to pediatric patients. We intended to produce consensus recommendations for the diagnosis and management of pediatric patients with C1-INH-HAE. METHODS: During an expert panel meeting that took place during the 9th C1-Inhibitor Deficiency Workshop in Budapest, 2015 [w w w.haenet. hu], pediatric data were presented and discussed and a consensus developed by voting. RESULTS: The symptoms of C1-INH-HAE often present in childhood. Differential diagnosis can be difficult as abdominal pain is common in pediatric C1-INH-HAE but also commonly occurs in the general pediatric population. The early onset of symptoms may predict a more severe subsequent course of the disease. Before the age of 1 year, C1-INH levels may be lower than in adults; therefore, it is advisable to confirm the diagnosis after the age of one year. All neonates/infants with an affected C1-INH-HAE family member should be screened for C1-INH deficiency. Pediatric patients should always carry a C1-INH-HAE information card, and medicine for emergency use. The regulatory approval status of the drugs for prophylaxis and for acute treatment is different in each country. Plasma-derived C1-INH, recombinant C1-INH, and ecallantide are the only agents licensed for the acute treatment of pediatric patients. Clinical trials are underway with additional drugs. It is recommended to follow-up patients in an HAE comprehensive care centre. CONCLUSIONS: The Pediatric-focused International Consensus for the diagnosis and management of C1-INH-HAE patients was created. This article is protected by copyright. All rights reserved. |
|
dc.relation.ispartof |
urn:issn:0105-4538 |
|
dc.title |
International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1-Inhibitor deficiency |
|
dc.type |
Journal Article |
|
dc.date.updated |
2017-02-03T12:00:41Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
3105440 |
|
dc.identifier.pubmed |
27503784 |
|
dc.contributor.department |
SE/AOK/K/I. Sz. Gyermekgyógyászati Klinika |
|
dc.contributor.department |
SE/AOK/K/III. Sz. Belgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|